Hugh J Willison Selected Research

Miller Fisher Syndrome (Fisher Syndrome)

1/2019	Current treatment practice of Guillain-Barré syndrome.
3/2016	C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy.
1/2014	Anti-GQ1b ganglioside positive Miller Fisher syndrome - evidence of paranodal pathology on nerve biopsy.
7/2009	Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles.
9/2008	C5 inhibitor rEV576 protects against neural injury in an in vitro mouse model of Miller Fisher syndrome.
5/2008	Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model.
1/2008	Anti-ganglioside antibodies and the presynaptic motor nerve terminal.
11/2005	Anti-disialosyl antibodies mediate selective neuronal or Schwann cell injury at mouse neuromuscular junctions.
10/2005	Recent developments in Miller Fisher syndrome and related disorders.
8/2005	Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hugh J Willison Research Topics

Disease

40	Guillain-Barre Syndrome 01/2022 - 04/2002
17	Miller Fisher Syndrome (Fisher Syndrome) 01/2019 - 04/2002
10	Peripheral Nervous System Diseases (PNS Diseases) 01/2018 - 12/2002
9	Infections 01/2021 - 09/2002
8	Paralysis (Palsy) 02/2012 - 09/2004
4	Zika Virus Infection 01/2022 - 04/2016
4	Enteritis 01/2018 - 07/2004
4	Ophthalmoplegia (External Ophthalmoplegia) 06/2005 - 04/2002
3	Demyelinating Diseases (Demyelinating Disease) 04/2017 - 01/2013
2	Encephalitis (Encephalitis, Rasmussen) 01/2022 - 10/2005
2	Central Nervous System Diseases (CNS Diseases) 01/2022 - 01/2021
2	Gliosis 06/2019 - 01/2019
2	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) 06/2011 - 11/2003
2	Ataxia (Dyssynergia) 06/2005 - 08/2002
1	Myasthenia Gravis 01/2022
1	Mitochondrial Diseases (Mitochondrial Disease) 11/2021
1	Arbovirus Infections 01/2021
1	COVID-19 01/2021
1	Dengue (Dengue Fever) 10/2020
1	Nervous System Diseases (Neurological Disorders) 01/2018
1	Alzheimer Disease (Alzheimer's Disease) 04/2017
1	acute flaccid myelitis 12/2016
1	Polyradiculoneuropathy (Polyradiculoneuritis) 03/2013
1	Polyneuropathies (Polyneuropathy) 10/2012
1	Necrosis 03/2012
1	Multiple Sclerosis 09/2011
1	Keratoconjunctivitis 01/2011
1	Gaucher Disease (Gaucher's Disease) 10/2008
1	Respiratory Paralysis 05/2008
1	Diarrhea 02/2008
1	Respiratory Tract Infections (Respiratory Tract Infection) 02/2008
1	Disease Progression 02/2008
1	Muscle Weakness 06/2005
1	Bacterial Infections (Bacterial Infection) 04/2004
1	Spider Bites (Spider Bite) 11/2003
1	Neuromuscular Diseases (Neuromuscular Disease) 10/2003

Drug/Important Bio-Agent (IBA)

37	GangliosidesIBA 01/2022 - 08/2002
37	AntibodiesIBA 01/2022 - 04/2002
15	AutoantibodiesIBA 01/2022 - 08/2002
11	Complement System Proteins (Complement)IBA 01/2022 - 11/2003
10	GlycolipidsIBA 01/2021 - 08/2002
6	Intravenous Immunoglobulins (IVIG)FDA Link 01/2019 - 10/2003
5	OligosaccharidesIBA 01/2018 - 08/2002
4	Immunoglobulin M (IgM)IBA 10/2020 - 12/2002
4	Immunoglobulin G (IgG)IBA 01/2018 - 02/2008
4	Proteins (Proteins, Gene)FDA Link 01/2018 - 06/2011
4	Polysaccharides (Glycans)IBA 01/2018 - 01/2011
4	Biomarkers (Surrogate Marker)IBA 08/2016 - 11/2009
4	alpha-latrotoxinIBA 11/2005 - 04/2002
3	Amantadine (Aman)FDA LinkGeneric 04/2016 - 02/2012
3	AntigensIBA 01/2014 - 10/2008
2	Immunoglobulins (Immunoglobulin)IBA 01/2021 - 07/2010
2	Heparin (Liquaemin)FDA LinkGeneric 06/2019 - 01/2019
2	Biological ProductsIBA 01/2017 - 08/2016
2	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 03/2016 - 08/2005
2	Glycoproteins (Glycoprotein)IBA 01/2014 - 01/2011
2	EpitopesIBA 11/2005 - 04/2004
2	LipopolysaccharidesIBA 07/2004 - 09/2002
1	TubulinIBA 01/2022
1	N-Methylaspartate (NMDA)IBA 01/2022
1	CalpainIBA 01/2022
1	CalciumIBA 01/2022
1	NAD+ Nucleosidase (NAD(P) Nucleosidase)IBA 01/2022
1	Mitochondrial DNA (mtDNA)IBA 11/2021
1	IV(4)-galactosyl-N-acetylganglioside GD1aIBA 01/2021
1	COVID-19 VaccinesIBA 01/2021
1	Viral RNAIBA 10/2020
1	Cell Adhesion MoleculesIBA 01/2018
1	Amyloid (Amyloid Fibrils)IBA 04/2017
1	Interferon Type IIBA 01/2017
1	Complement C5 (Complement 5)IBA 03/2016
1	GlycosphingolipidsIBA 02/2014
1	LipidsIBA 09/2011
1	Oligoclonal BandsIBA 09/2011
1	Botulinum Toxins (Botulinum Toxin)IBA 12/2008
1	eculizumab FDA Link 05/2008
1	Neurotransmitter Agents (Neurotransmitter)IBA 11/2005
1	Prednisolone (Predate)FDA LinkGeneric 11/2003
1	calpain inhibitorsIBA 11/2003
1	Therapeutic UsesIBA 10/2003
1	Acetylcholine (Acetylcholine Chloride)FDA Link 04/2002

Therapy/Procedure

3	Plasma Exchange 01/2019 - 12/2016
2	Critical Care (Surgical Intensive Care) 10/2020 - 04/2016
2	Therapeutics 01/2018 - 10/2005
1	Artificial Respiration (Mechanical Ventilation) 01/2021
1	Length of Stay 10/2020
1	Immunotherapy 01/2019
1	Intraperitoneal Injections 05/2008
1	Intravenous Injections 05/2008
1	Plasmapheresis 10/2005